symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
APLT,2.63,1.559873,884914,166016646,0,0.625-3.11,-0.19,"Applied Therapeutics, Inc.",USD,0001697532,US03828A1016,03828A101,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.appliedtherapeutics.com,"Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.",Dr. Shoshana  Shendelman Ph.D.,Healthcare,US,22,212 220 9226,545 Fifth Avenue,New York,NY,10017,2.10515,3.16515,https://financialmodelingprep.com/image-stock/APLT.png,2019-05-14,False,False,True,False,False
